Search Results - "LOUIE, Arthur C" :: K.UTB vyhledávací portál | TBU Library Retrieval Portal

Randomized Study of CPX-351 for Medically Less-Fit Adults with Newly Diagnosed Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasm

Randomized Study of CPX-351 for Medically Less-Fit Adults with Newly Diagnosed Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasm

by Walter, Roland B., Othus, Megan, Orlowski, Kaysey F., McDaniel, Emily N., Scott, Bart L., Becker, Pamela S., Percival, Mary-Elizabeth M., Hendrie, Paul C., Medeiros, Bruno C, Chiarella, Michael T., Louie, Arthur C., Estey, Elihu H.
Published in Blood (08.12.2017)

Get full text

Journal Article

The Impact of Hematopoietic Cell Transplantation on Survival: An Exploratory Analysis of a Phase 3 Study of CPX-351 Versus 7+3 in Older Patients with Newly Diagnosed, High-Risk/Secondary AML

The Impact of Hematopoietic Cell Transplantation on Survival: An Exploratory Analysis of a Phase 3 Study of CPX-351 Versus 7+3 in Older Patients with Newly Diagnosed, High-Risk/Secondary AML

by Lin, Tara L, Cortes, Jorge E., Newell, Laura F., Ritchie, Ellen K., Stuart, Robert K., Strickland, Stephen A., Hogge, Donna, Solomon, Scott R, Stone, Richard M., Bixby, Dale L., Kolitz, Jonathan E., Schiller, Gary J., Wieduwilt, Matthew J., Ryan, Daniel H., Ryan, Robert, Chiarella, Michael, Louie, Arthur C., Uy, Geoffrey L.
Published in Blood (29.11.2018)

Get full text

Journal Article

Efficacy and Safety of CPX-351 Versus 7+3 in a Subgroup of Older Patients with Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Enrolled in a Phase 3 Study

Efficacy and Safety of CPX-351 Versus 7+3 in a Subgroup of Older Patients with Newly Diagnosed Acute Myeloid Leukemia with Myelodysplasia-Related Changes (AML-MRC) Enrolled in a Phase 3 Study

by Ryan, Daniel H., Uy, Geoffrey L., Cortes, Jorge E., Newell, Laura F., Ritchie, Ellen K., Stuart, Robert K., Strickland, Stephen A., Hogge, Donna, Solomon, Scott R, Stone, Richard M., Bixby, Dale L., Kolitz, Jonathan E., Schiller, Gary J., Wieduwilt, Matthew J., Ryan, Robert, Chiarella, Michael, Louie, Arthur C., Lancet, Jeffrey E.
Published in Blood (29.11.2018)

Get full text

Journal Article

CPX-351 ((Cytarabine:Daunorubicin) Liposome Injection, (Vyxeos)) Does Not Prolong Qtcf Intervals, Requires No Dose Adjustment for Impaired Renal Function and Induces High Rates of Complete Remission in Acute Myeloid Leukemia

CPX-351 ((Cytarabine:Daunorubicin) Liposome Injection, (Vyxeos)) Does Not Prolong Qtcf Intervals, Requires No Dose Adjustment for Impaired Renal Function and Induces High Rates of Complete Remission in Acute Myeloid Leukemia

by Lin, Tara L., Newell, Laura F., Stuart, Robert K., Michaelis, Laura C., Rubenstein, Stephen E., Pentikis, Helen S., Callahan, Timothy, Alvarez, Donna, Mayer, Lawrence D., Louie, Arthur C.
Published in Blood (03.12.2015)

Get full text

Journal Article

Efficacy and Safety of CPX-351 Versus 7+3 in Older Adults with Secondary Acute Myeloid Leukemia: Combined Subgroup Analysis of Phase 2 and Phase 3 Studies

Efficacy and Safety of CPX-351 Versus 7+3 in Older Adults with Secondary Acute Myeloid Leukemia: Combined Subgroup Analysis of Phase 2 and Phase 3 Studies

by Lancet, Jeffrey E., Ritchie, Ellen K, Uy, Geoffrey L., Medeiros, Bruno C, Newell, Laura F., Lin, Tara L., Hogge, Donna, Stuart, Robert K., Strickland, Stephen A, Solomon, Scott R, Stone, Richard M., Kolitz, Jonathan E., Bixby, Dale L., Schiller, Gary J., Wieduwilt, Matthew J., Kovacsovics, Tibor, Ryan, Robert J., Chiarella, Michael, Louie, Arthur C, Cortes, Jorge E.
Published in Blood (08.12.2017)

Get full text

Journal Article

Multivariate Efficacy Analysis of a Randomized, Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Treatment-Related Acute Myeloid Leukemia (AML) or AML with Myelodysplasia-Related Changes

Multivariate Efficacy Analysis of a Randomized, Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Treatment-Related Acute Myeloid Leukemia (AML) or AML with Myelodysplasia-Related Changes

by Uy, Geoffrey L., Lancet, Jeffrey E., Cortes, Jorge E., Newell, Laura F., Lin, Tara L., Ritchie, Ellen K, Stuart, Robert K., Strickland, Stephen A, Hogge, Donna, Solomon, Scott R, Stone, Richard M., Bixby, Dale L., Kolitz, Jonathan E., Schiller, Gary J., Wieduwilt, Matthew J., Shemanski, Lynn, Chiarella, Michael, Louie, Arthur C, Medeiros, Bruno C
Published in Blood (08.12.2017)

Get full text

Journal Article

$Subanalysis of Patients with Secondary Acute Myeloid Leukemia (sAML) with Refractory Anemia with Excess of Blasts in Transformation (RAEB-t) Enrolled in a Phase 3 Study of CPX-351 Versus Conventional 7+3 Cytarabine and Daunorubicin$

Subanalysis of Patients with Secondary Acute Myeloid Leukemia (sAML) with Refractory Anemia with Excess of Blasts in Transformation (RAEB-t) Enrolled in a Phase 3 Study of CPX-351 Versus Conventional 7+3 Cytarabine and Daunorubicin

by Lin, Tara L., Uy, Geoffrey L., Wieduwilt, Matthew J., Newell, Laura F., Stuart, Robert K., Medeiros, Bruno C, Schiller, Gary J., Rubenstein, Eric, Stock, Wendy, Warlick, Erica D., Foster, Matthew, Bixby, Dale L., Podoltsev, Nikolai A., An, Qi, Faderl, Stefan, Louie, Arthur C., Lancet, Jeffrey E.
Published in Blood (08.12.2017)

Get full text

Journal Article

Rates of Adverse Events per Patient-Year in a Randomized, Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, Treatment-Related Acute Myeloid Leukemia (AML) or AML with Myelodysplasia-Related Changes

Rates of Adverse Events per Patient-Year in a Randomized, Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, Treatment-Related Acute Myeloid Leukemia (AML) or AML with Myelodysplasia-Related Changes

by Medeiros, Bruno C, Lancet, Jeffrey E., Cortes, Jorge E., Newell, Laura F., Lin, Tara L., Ritchie, Ellen K, Stuart, Robert K., Strickland, Stephen A., Hogge, Donna, Solomon, Scott R, Stone, Richard M., Bixby, Dale L., Kolitz, Jonathan E., Schiller, Gary J., Wieduwilt, Matthew J., Ryan, Robert J., Chiarella, Michael, Louie, Arthur C, Uy, Geoffrey L.
Published in Blood (08.12.2017)

Get full text

Journal Article

Outcomes in Older Patients with Newly Diagnosed, High-risk/Secondary Acute Myeloid Leukemia (sAML) Who Received Consolidation in a Phase 3 Study of CPX-351 versus Conventional 7+3/5+2 Cytarabine and Daunorubicin

Outcomes in Older Patients with Newly Diagnosed, High-risk/Secondary Acute Myeloid Leukemia (sAML) Who Received Consolidation in a Phase 3 Study of CPX-351 versus Conventional 7+3/5+2 Cytarabine and Daunorubicin

by Kolitz, Jonathan, Strickland, Stephen A., Cortes, Jorge E., Hogge, Donna, Lancet, Jeffrey E., Goldberg, Stuart, Ryan, Robert J., Chiarella, Michael, Louie, Arthur C., Uy, Geoffrey L.
Published in Clinical lymphoma, myeloma and leukemia (01.09.2018)

Get full text

Journal Article

Randomized Study of Liposomal Cytarabine and Daunorubicin (CPX-351) for Adults with Untreated High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) at High Risk of Treatment-Related Mortality

Randomized Study of Liposomal Cytarabine and Daunorubicin (CPX-351) for Adults with Untreated High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) at High Risk of Treatment-Related Mortality

by Walter, Roland B., Orlowski, Kaysey F., Powell, Morgan A., Becker, Pamela S., Hendrie, Paul C., Ostronoff, Fabiana, Ranker, Elizabeth M., Othus, Megan, Louie, Arthur C., Estey, Elihu H.
Published in Blood (06.12.2014)

Get full text

Journal Article

Analysis of Efficacy By Age for Patients Aged 60-75 with Untreated Secondary Acute Myeloid Leukemia (AML) Treated with CPX-351 Liposome Injection Versus Conventional Cytarabine and Daunorubicin in a Phase III Trial

Analysis of Efficacy By Age for Patients Aged 60-75 with Untreated Secondary Acute Myeloid Leukemia (AML) Treated with CPX-351 Liposome Injection Versus Conventional Cytarabine and Daunorubicin in a Phase III Trial

by Medeiros, Bruno C., Lancet, Jeffrey E., Cortes, Jorge E., Newell, Laura F, Lin, Tara L., Ritchie, Ellen K., Stuart, Robert K., Strickland, Stephen A., Hogge, Donna, Solomon, Scott R., Stone, Richard M., Bixby, Dale L., Kolitz, Jonathan E., Schiller, Gary J., Wieduwilt, Matthew J., Ryan, Daniel H., Hoering, Antje, Chiarella, Michael T., Louie, Arthur C., Uy, Geoffrey L.
Published in Blood (02.12.2016)

Get full text

Journal Article

Survival Following Allogeneic Hematopoietic Cell Transplantation in Older High-Risk Acute Myeloid Leukemia Patients Initially Treated with CPX-351 Liposome Injection Versus Standard Cytarabine and Daunorubicin: Subgroup Analysis of a Large Phase III Trial

Survival Following Allogeneic Hematopoietic Cell Transplantation in Older High-Risk Acute Myeloid Leukemia Patients Initially Treated with CPX-351 Liposome Injection Versus Standard Cytarabine and Daunorubicin: Subgroup Analysis of a Large Phase III Trial

by Lancet, Jeffrey E., Hoering, Antje, Uy, Geoffrey L., Cortes, Jorge E., Newell, Laura F, Lin, Tara L., Ritchie, Ellen K., Stuart, Robert K., Strickland, Stephen A., Hogge, Donna, Solomon, Scott R., Stone, Richard M., Bixby, Dale L., Kolitz, Jonathan E., Schiller, Gary J., Wieduwilt, Matthew J., Ryan, Daniel H., Chiarella, Michael T., Louie, Arthur C., Medeiros, Bruno C.
Published in Blood (02.12.2016)

Get full text

Journal Article

$A Phase 3 Study of CPX-351 versus Conventional 7+3 Cytarabine and Daunorubicin: Subanalysis of Patients with Secondary Acute Myeloid Leukemia (sAML) with Refractory Anemia with Excess of Blasts in Transformation (RAEB-t)$

A Phase 3 Study of CPX-351 versus Conventional 7+3 Cytarabine and Daunorubicin: Subanalysis of Patients with Secondary Acute Myeloid Leukemia (sAML) with Refractory Anemia with Excess of Blasts in Transformation (RAEB-t)

by Lin, Tara L., Wieduwilt, Matthew J., Newell, Laura F., Schiller, Gary J., Rubenstein, S. Eric, Stock, Wendy, Warlick, Erica, Bixby, Dale L., Podoltsev, Nikolai, An, Qi, Faderl, Stefan, Louie, Arthur C., Uy, Geoffrey L.
Published in Clinical lymphoma, myeloma and leukemia (01.09.2018)

Get full text

Journal Article

CPX-351 Is Effective in Newly Diagnosed Older Patients with AML and with Multiple Risk Factors

CPX-351 Is Effective in Newly Diagnosed Older Patients with AML and with Multiple Risk Factors

by Lancet, Jeffrey E, Cortes, Jorge E, Kovacsovics, Tibor, Hogge, Donna E., Kolitz, Jonathan E., Tallman, Martin S, Hoering, Antje, Chiarella, Michael T., Louie, Arthur C., Feldman, Eric
Published in Blood (16.11.2012)

Get full text

Journal Article

Significance of Prior HSCT on the Outcome of Salvage Therapy with CPX-351 or Conventional Chemotherapy Among First Relapse AML Patients

Significance of Prior HSCT on the Outcome of Salvage Therapy with CPX-351 or Conventional Chemotherapy Among First Relapse AML Patients

by Cortes, Jorge E., Feldman, Eric J, Goldberg, Stuart L., Rizzieri, David A., Louie, Arthur C., Kolitz, Jonathan E.
Published in Blood (18.11.2011)

Get full text

Journal Article

CPX-351: A Randomized Phase 2b Study of CPX-351 v. Intensive Salvage Therapy in '65 Yo First Relapse AML Patients: Initial Efficacy and Safety Report

CPX-351: A Randomized Phase 2b Study of CPX-351 v. Intensive Salvage Therapy in '65 Yo First Relapse AML Patients: Initial Efficacy and Safety Report

by Cortes, Jorge E., Feldman, Eric J, Goldberg, Stuart L., Rizzieri, David A., Paulsen, Kim H., Louie, Arthur C., Kolitz, Jonathan E.
Published in Blood (18.11.2011)

Get full text

Journal Article

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy

by Fyfe, G, Fisher, R I, Rosenberg, S A, Sznol, M, Parkinson, D R, Louie, A C
Published in Journal of clinical oncology (01.03.1995)

Get more information

Journal Article

Abstract 1292: Pharmacokinetics of CPX-351: A nano-scale liposomal fixed molar ratio of cytarabine-daunorubicin (Cyt:Daun) in patients with advanced leukemia

Abstract 1292: Pharmacokinetics of CPX-351: A nano-scale liposomal fixed molar ratio of cytarabine-daunorubicin (Cyt:Daun) in patients with advanced leukemia

by Feldman, Eric J., Lancet, Jeffrey E., Kolitz, Jonathan E., Trang, John M., Mayer, Lawrence D., Swenson, Chris E., Chiarella, Michael T., Louie, Arthur C.
Published in Cancer research (Chicago, Ill.) (15.04.2011)

Get full text

Journal Article

Phase 2B Randomized Study of CPX-351 Vs. Cytarabine (CYT) + Daunorubicin (DNR) (7+3 Regimen) In Newly Diagnosed AML Patients Aged 60–75

Phase 2B Randomized Study of CPX-351 Vs. Cytarabine (CYT) + Daunorubicin (DNR) (7+3 Regimen) In Newly Diagnosed AML Patients Aged 60–75

by Lancet, Jeffrey E., Cortes, Jorge E., Hogge, Donna E., Tallman, Martin, Kovacsovics, Tibor, Damon, Lloyd E., Ritchie, Ellen, Komrokji, Rami S., Louie, Arthur C., Feldman, Eric J
Published in Blood (19.11.2010)

Get full text

Journal Article

Phase IIb Randomized Study of CPX-351 Vs. Conventional Cytarabine + Daunorubicin in Newly Diagnosed AML Patients Aged 60-75: Safety Report

Phase IIb Randomized Study of CPX-351 Vs. Conventional Cytarabine + Daunorubicin in Newly Diagnosed AML Patients Aged 60-75: Safety Report

by Lancet, Jeffrey E, Feldman, Eric J., Kolitz, Jonathan E., Tallman, Martin S., Hogge, Donna E., Komrokji, Rami S., Chiarella, Michael T., Louie, Arthur C.
Published in Blood (20.11.2009)

Get full text

Journal Article